The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT;Příprava myelom-specifických T lymfocytů aktivovaných dendritickými buňkami naloženými nonapeptidy odvozenými od mucinového proteinu MUC1 a katalytické podjednotky telomerázy hTERT

Klinicka Onkologie

Volumn 21, Issue 2, 2008, Pages 59-65

  Očadlíková, Darina ^a   Kovarova L ^a   Hajek R ^a   Michalek J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

HTERT; Immunotherapy; Interferon gamma; MUC1 protein; Multiple myeloma

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; MUCIN 1; NONAPEPTIDE; TELOMERASE; TUMOR ANTIGEN; CANCER VACCINE; EPITOPE; TERT PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; BLOOD DONOR; CELL ACTIVATION; CELL EXPANSION; CELL SEPARATION; CELL STIMULATION; CYTOMETRY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME ACTIVE SITE; FEASIBILITY STUDY; FLOW CYTOMETRY; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY; IN VITRO STUDY; MYELOMA CELL; T LYMPHOCYTE; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA;

ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; EPITOPES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MUCIN-1; MULTIPLE MYELOMA; T-LYMPHOCYTES; TELOMERASE;

EID: 42249099000     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hájek R. Základní algoritmus léčby mnohočetného myelomu. Transfuze a hematologie dnes. 2005; 11: (26-30).
2. Barlogie B, Jagannath S, Vesole DH, Trikot G. Autologous and allogeneic transplants for multiple myeloma. Semin.Hematol. 1995; 32: 31-44.
3. Facon T. Frontline treatment in patients not eligible for stem cell transplantation. XIth International Myeloma Workshop, IVth International Workshop on Waldenström's Macroglobulinemia, 25-30 June 2007 - Kos Island, Greece, The hematology journal. 2007; (abstr. S 5.5).
4. Cavo M. The role of thalidomide in myeloma patients eligible for high-dose therapy. XIth International Myeloma Workshop, IVth International Workshop on Waldenström's Macroglobulinemia, 25-30 June 2007 - Kos Island, Greece, The hematology journal. 2007; (abstr. S 5.2).
5. Jagannath S. The role of Bortezomib in myeloma patients eligible for high-dose therapy. XIth International Myeloma Workshop, IVth International Workshop on Waldenström's Macroglobulinemia, 25-30 June 2007 - Kos Island, Greece, The hematology journal. 2007; (abstr. S 5.3).
6. Richardson PG and Anderson KC. Multiple myeloma. Remedica Publishing. 2004; 3: 57.
7. Adam Z, Hájek R, Ščudla V a kol. Mnohočetný myelom a další monoklonální gamapatie. Masarykova Univerzita Brno. 1999; 1-260.
8. Hájek R, Büchler T, Musilová R, Kř ivanová A. Perspektivní léky v léčbě mnohočetného myelomu. Klinická onkologie. 2002; suppl.: 38-42.
9. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-1678.
10. Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 2004; 4: 1081-1096.
11. Barlogie B, Jagannath S, Epstein J, et al. Biology and therapy of multiple myeloma in 1996. Semin Hematol 1997; 34: 67-72.
12. Yi Q, Österborg A. Idiotype-specific T cells in multiple myeloma:targets for an immunotherapeutic intervention?. Med.Oncol 1996; 13: 1-7.
13. Büchler T, Hajek R. Dendritic cell vaccines in the treatment of multiple myeloma. Med Oncol 2002; 19: 213-308.
14. Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cells-based immunotherapy in multiple myeloma. Br J Hematol 2002;117:297-305.
15. Wen YJ, Min R, Yi Q, et al. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma-promissing effector cells for immunotherapy. Blood 2002; 99: 3280-3285.
16. Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of myeloma-specific cytotoxic T-lymphocytes. Blood 2003; 4: 1435-1442.
17. Reichardt V, Milazzo C, Brossart P, et al. Induction of myeloma specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. The 44th Annual Meeting of the American Society of Hematology 2002; (abstr. 3182).
18. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol. 2001; 29:1247-1255.
19. Minev B, Hipp J, Zanetti M, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. PNAS. 2000; 97: 4796-4801.
20. Fajkus J. Jak začínají a končí chromozomy, rub a líc buněčné nesmrtelnosti. Živa. 2002; 6: 245-248.
21. Shay JW, Bacchetti S. A survey of telomerase activity in humen cancer. Eur J Cancer. 1997; 33: 787-791.
22. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999; 10: 673-690.
23. Vonderheide RH, Schultze JL, Anderson KS, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61: 8366-8370.
24. Vonderheide RH. Telomerase as a universal tumor-associated antigens for cancer immunotherapy. Oncogene. 2002; 21: 674-679.
25. Pang JX. Human telomerase reverse transcriptase as a target for tumor immunotherapy. Ai Zheng. 2003; 22: 893-895.
26. Arai J, Yasukawa M, Fujita S, et al. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T-lymphocytes. Blood. 2001; 97: 2903-2907.
27. Matthews P, Jones CJ. Clinical implications of telomerase detection. Histopathology. 2001; 38: 485-489.
28. Vonderheide RH, Domchek SM, Chen D-Y, et al. Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T lymphocytes. Clinical Cancer Research. 2004; 10: 828-839.
29. Gendler S, Taylor-Papadimitriou J, Burchell J-A, et al. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem-repeats. J Biol Chem.1988; 263: 12820-12823.
30. Finn OJ, Jerome KR, Henderson RA, et al. MUC1 epithelial tumor-mucin-based immunity and cancer vaccines. Immunol Rev. 1995; 145: 61-89.
31. Hinoda Y, Nakagawa N, Yachi A, et al. Recognition of the polypeptide core of mucin by monoclonal antibody MUSE 11 against an adenocarcinoma-associated antigen. Jpn.J.Cancer Res. 1990; 81:1206.
32. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol. 2001; 29:1247-1255.
33. Takahashi T, Makiguchi Y, Yachi A, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. Journal of Immunology. 1994; 153: 2102-2109.
34. Treon SP, Raje N, and Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin. Oncol. 2000; 27: 598-613.
35. Burton J, Mishina D, Gold DV, et al. Epithelial Mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. Clin Cancer Res. 1999; 5: 3065-3072.
36. Noto H, Takahashi T, Hinoda Y, et al. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int. Immunol. 1997; 9: 791-798.
37. Appostopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur J Immunol. 1997; 27: 2579-2585.
38. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000; 96: 3102-3108.
39. Wierecky J, Mueller MR, Brossart P, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006; 66: 5910-5918.
40. Brugger W, Buhring HJ, Kanz L, et al. Expression of MUC1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J.Clin.Oncol. 1999; 17:1535-1544.
41. Agrawal B, Reddish MA, Longenecker BM, et al. The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences. Cancer Res. 1998; 58: 5151-5156.
42. Gong J, Apostopoulos V, Kufe D, et al. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology. 2000; 101: 316-324.
43. Büchler T, Hájek R, Bourková L a kol. Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. Vaccine. 2003; 21: 877-882.
44. Očadlíková D, Kovářová L, Vidláková P a kol. Identifikace myelomspecifických T-lymfocytů na základě produkce interferonu gama. Edukační sborník XXVIII. Brněnské onkologické dny a XVIII. Konference pro sestry a laboranty 26.-28.května 2004. 2004; 53: 113-116.
45. Beckove H, Witzens M, Choi C, et al. MUC-1-reactive cytotoxic memory T cells in bone marrow of myeloma patients. The 44th Annual Meeting of the American Society of Hematology 2003, Blood. 2003; (abstr. 5227).
46. Yi Q, Qian J, Xie J, et al. Generation of tumor-specific cytotoxic T lymphocytes in multiple myeloma using dendritic cells pulsed with tumor-derived heat shock protein gp96. The 44th Annual Meeting of the American Society of Hematology 2004, Blood. 2004; (abstr. 2451).